Properties (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
CureMatch,_Inc.
|
| gptkbp:CEO |
gptkb:Ming_Hsieh
|
| gptkbp:employees |
Over 300
|
| gptkbp:focus |
Precision medicine
|
| gptkbp:founded |
2016
|
| gptkbp:founder |
gptkb:Ming_Hsieh
|
| gptkbp:headquarters |
gptkb:Temple_City,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fulgent Genetics, Inc.
|
| gptkbp:industry |
Genomics
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:market |
Global
|
| gptkbp:partnerships |
Various healthcare institutions
|
| gptkbp:revenue |
$100 million (2020)
|
| gptkbp:service_area |
Bioinformatics
Cardiology Community outreach Health informatics Oncology Clinical trials Neurology Quality assurance Data analytics Infectious diseases Patient education Pharmaceutical services Regulatory compliance Accreditation services Public health initiatives Genetic counseling Laboratory accreditation Research services Pharmacogenomics Laboratory services Telehealth services Whole genome sequencing Newborn screening Prenatal testing Clinical decision support Rare diseases Health policy advocacy Tumor profiling Carrier screening Targeted gene panels Whole exome sequencing Patient management Liquid biopsy Custom testing solutions Diagnostic_services Clinical_laboratory_improvement_amendments_(CLIA) |
| gptkbp:services |
Genetic testing
|
| gptkbp:stockSymbol |
FLGT
|
| gptkbp:subsidiary |
Fulgent_Therapeutics
|
| gptkbp:technology |
Next-generation sequencing
|
| gptkbp:type |
Public company
|
| gptkbp:website |
www.fulgentgenetics.com
|